Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Abiraterone Acetate × Androgen Antagonists × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 109 Neoplasm Metastasis 11 Prostate Cancer Metastatic 4 Adenocarcinoma 3 Prostatic Diseases 2 Prostate CA 2 Oligometastatic Prostate Cancer 2 Neoplasms 2 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2 Metastatic Hormone-sensitive Prostate Cancer 2 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Stage IV Prostate Adenocarcinoma AJCC v7 1 Stage I Prostate Adenocarcinoma 1 Salivary Gland Neoplasms 1 Recurrence 1 Radiation Injuries 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Adenocarcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 PSA Level Greater Than 0.03 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 Metastatic Hormone-Sensitive Prostate Cance 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer 1 Metastatic Castrate-sensitive Prostate Cancer 1 Lymphatic Metastasis 1 Intraprostatic Prostate Cancer 1 Insulin Resistance 1

Interventions

Prednisolone 1 BID protein, human 1 Androgen Antagonists 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06768255 2025-01-10

mCRPC

Fudan University

Phase 3 Not yet recruiting

Abiraterone Acetate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡